Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib.
Year: 2023
Type: article
Study design: Case Report
Abstract: Despite the existence of effective first and second line therapy options for patients with colorectal cancer, heavily treated patients have limited additional therapies. Genomic profiling is a promising tool for guiding subsequent treatment selection. Here, we describe the results of treating a colorectal cancer patient with molecularly-matched therapy based on the results of genomic profiling. The patient received a combination of afatinib and bevacizumab due to the presence of ERRFI1 variant. To our knowledge, this is the first report on the effect of EGFR inhibitors in patients with ERRFI1-altered RAS/BRAF wild-type colorectal adenocarcinoma.
Source: PubMed Central
Institutions: Russian Cancer Research Center NN Blokhin, Lomonosov Moscow State University, National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of the Russian Federation, Moscow Multidisciplinary Clinical Center "Kommunarka", Moscow Institute of Physics and Technology, Central Clinical Hospital and Polyclinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4387764520